This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Three-Year Clinical Outcomes From STROLL Trial Demonstrate Sustained Durability And Performance Of S.M.A.R.T.® Stent For Treatment Of Peripheral Artery Disease

Cordis Corporation today announced three-year clinical outcomes from the STROLL Trial at the Abstracts and Late Breaking Clinical Trials session at the 26 th Annual International Symposium on Endovascular Therapy (ISET). Results from the trial showed that patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) treated with the S.M.A.R.T. ® Vascular Stent System (S.M.A.R.T. ® Stent) experienced sustained clinical and quality of life benefits out to three years, including improvements in physical, psychological and social function.

“These results demonstrate that the S.M.A.R.T. ® Stent performs well in patients suffering from peripheral artery disease three years after treatment,” said Michael R. Jaff, D.O., lead author of the study and chair of the Institute for Health, Vascular and Stroke Care at Massachusetts General Hospital. “Patients had sustained improvements in walking distance and speed, and continued to experience enhanced health related quality of life.”

In the study, the average lesion length was 77 mm, 23.6% of patients had total occlusions in the superficial femoral artery and 47% of patients were diabetic. At three years, freedom from clinically driven target lesion revascularization (TLR) was 78.5% and the primary patency rate was 72.3% by Kaplan Meier estimate. The stent fracture rate remained low at 3.6% and all stent fractures were Type I, least severe, with no incidents of more severe stent fractures (Type II-V). The mean ankle-brachial index (ABI) improved from 0.66±0.15 at baseline to 0.93±0.18 at one year and remained at 0.92±0.20 at three years. Patients in the STROLL Trial also experienced clinically meaningful improvements in patient reported Health Related Quality of Life (HRQOL), such as pain, walking distance and walking speed that were maintained out to three years. At three years, there was significant improvement on the (Peripheral Artery Questionnaire) PAQ summary scale (mean change 28 points, p<0.001).

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs